The Claim
Baseline use of sulfonylureas or insulin is associated with a reduced likelihood of achieving glycemic control following GLP-1 receptor agonist therapy in adults with type 2 diabetes.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults with type 2 diabetes who were already taking sulfonylureas or insulin before starting GLP-1 receptor agonist therapy are less likely to reach target blood sugar levels than those who were not.
See the scientific wording
Use of sulfonylureas or insulin at baseline is associated with reduced likelihood of achieving glycemic control after GLP-1 receptor agonist therapy in adults with type 2 diabetes, reflecting more advanced or treatment-resistant disease.
Long-term use of insulin or sulfonylureas forces the pancreas to produce more insulin than it can sustain, which wears out the insulin-producing cells. When GLP-1 drugs try to boost insulin release later, these damaged cells cannot respond strongly enough to lower blood sugar.
What the research says
1 studyPeople who were already taking insulin or sulfonylureas before starting GLP-1 drugs were less likely to get their blood sugar under control, because their diabetes was already more serious — and the study’s computer model found this pattern clearly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.